NCT06217406View on ClinicalTrials.gov

Preemptive Treatment With Acyclovir in Intubated and Mechanically Ventilated Patients With Herpes (PTH2)

NANot yet recruitingINTERVENTIONAL
Enrollment

246

Participants

Timeline

Start Date

March 1, 2024

Primary Completion Date

March 1, 2027

Study Completion Date

March 1, 2027

Conditions
Invasive Mechanical VentilationHSV Throat Reactivation
Interventions
DRUG

Intravenous acyclovir (ACYCLOVIR )

Patients randomized in the experimental arm will receive intravenous acyclovir at a dosing of 5 mg/kg/8 hours during 14 days (treatment will be stopped at ICU discharge).

DRUG

Saline bags

Patients randomized in the control arm will receive placebo, eg. saline bags (same volume as acyclovir bags) every 8 hours during 14 days (treatment will be stopped in case of ICU discharge).

All Listed Sponsors
lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT06217406 - Preemptive Treatment With Acyclovir in Intubated and Mechanically Ventilated Patients With Herpes (PTH2) | Biotech Hunter | Biotech Hunter